GlassScriptPhysician profile
Paul Ren Chu
NPI 1477558658
$11,004.26
in general payments reported to CMS, 2019-2025
43 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,475 · 2020: $965 · 2021: $1,271 · 2022: $1,264 · 2023: $1,476 · 2024: $1,327 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,030.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,030.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,002.94 | 2019-2020 | |
| Amgen INC. | $1,261.30 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $905.18 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $897.78 | 2019-2025 | |
| Boston Scientific Corporation | $784.65 | 2019-2025 | Watchman Flx, Emblem Mri S-Icd, Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $618.76 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $521.33 | 2020-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $459.74 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $453.52 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $404.40 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.48 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $380.18 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $252.71 | 2019-2025 | Farxiga, Wainua |
| Amarin Pharma, INC. | $208.92 | 2019-2022 | |
| Biotronik INC. | $117.16 | 2019-2025 | Amvia Edge, Biomonitor |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.